These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20421983)

  • 1. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad.
    Madar-Balakirski N; Tempel-Brami C; Kalchenko V; Brenner O; Varon D; Scherz A; Salomon Y
    PLoS One; 2010 Apr; 5(4):e10282. PubMed ID: 20421983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
    BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
    Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR
    Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice.
    Neuschmelting V; Kim K; Malekzadeh-Najafabadi J; Jebiwott S; Prakash J; Scherz A; Coleman JA; Kircher MF; Ntziachristos V
    Theranostics; 2018; 8(3):723-734. PubMed ID: 29344301
    [No Abstract]   [Full Text] [Related]  

  • 5. Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.
    Koudinova NV; Pinthus JH; Brandis A; Brenner O; Bendel P; Ramon J; Eshhar Z; Scherz A; Salomon Y
    Int J Cancer; 2003 May; 104(6):782-9. PubMed ID: 12640688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP).
    Preise D; Scherz A; Salomon Y
    Photochem Photobiol Sci; 2011 May; 10(5):681-8. PubMed ID: 21258718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
    Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
    BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model.
    Chevalier S; Cury FL; Scarlata E; El-Zayat E; Hamel L; Rocha J; Zouanat FZ; Moussa S; Scherz A; Elhilali M; Anidjar M
    J Urol; 2013 Nov; 190(5):1946-53. PubMed ID: 23680311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
    Sjoberg HT; Philippou Y; Magnussen AL; Tullis IDC; Bridges E; Chatrian A; Lefebvre J; Tam KH; Murphy EA; Rittscher J; Preise D; Agemy L; Yechezkel T; Smart SC; Kinchesh P; Gilchrist S; Allen DP; Scheiblin DA; Lockett SJ; Wink DA; Lamb AD; Mills IG; Harris A; Muschel RJ; Vojnovic B; Scherz A; Hamdy FC; Bryant RJ
    Br J Cancer; 2021 Aug; 125(4):534-546. PubMed ID: 34155340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prompt assessment of WST11-VTP outcome using luciferase transfected tumors enables second treatment and increase in overall therapeutic rate.
    Fleshker S; Preise D; Kalchenko V; Scherz A; Salomon Y
    Photochem Photobiol; 2008; 84(5):1231-7. PubMed ID: 18399928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.
    Kim K; Zhang H; La Rosa S; Jebiwott S; Desai P; Kimm S; Scherz A; O'Donoghue JA; Weber WA; Coleman JA
    Clin Cancer Res; 2017 Jul; 23(13):3343-3351. PubMed ID: 28108545
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity.
    Preise D; Oren R; Glinert I; Kalchenko V; Jung S; Scherz A; Salomon Y
    Cancer Immunol Immunother; 2009 Jan; 58(1):71-84. PubMed ID: 18488222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.
    Lebdai S; Villers A; Barret E; Nedelcu C; Bigot P; Azzouzi AR
    World J Urol; 2015 Jul; 33(7):965-71. PubMed ID: 25614256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
    Trachtenberg J; Weersink RA; Davidson SR; Haider MA; Bogaards A; Gertner MR; Evans A; Scherz A; Savard J; Chin JL; Wilson BC; Elhilali M
    BJU Int; 2008 Aug; 102(5):556-62. PubMed ID: 18494829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI.
    Gross S; Gilead A; Scherz A; Neeman M; Salomon Y
    Nat Med; 2003 Oct; 9(10):1327-31. PubMed ID: 14502284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.
    Azzouzi AR; Barret E; Bennet J; Moore C; Taneja S; Muir G; Villers A; Coleman J; Allen C; Scherz A; Emberton M
    World J Urol; 2015 Jul; 33(7):945-53. PubMed ID: 25712310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
    Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
    Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
    [No Abstract]   [Full Text] [Related]  

  • 18. Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.
    Azzouzi AR; Lebdai S; Benzaghou F; Stief C
    World J Urol; 2015 Jul; 33(7):937-44. PubMed ID: 25786708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: TOOKAD® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Cadeddu JA
    J Urol; 2014 May; 191(5):1290. PubMed ID: 24745491
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: TOOKAD ® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Taneja SS
    J Urol; 2014 Apr; 191(4):983-4. PubMed ID: 24703118
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.